The Glucagon Paradox in Next-Generation Incretin Therapy: How GLP-1, GIP, and Glucagon Receptor Co-Agonism May Amplify Weight Loss Despite Glucagons Hyperglycemic Biology Abstract The development of dual and triple incretin-based receptor agonists represents a major advance in the pharmacologic treatment of obesity, type 2 diabetes, and related cardiometabolic disease
There is no comparable level of evidence for other autoimmune conditions at this time
doi: 10.3389/fonc.2023.1099811
Many customers report noticing improvements in skin brightness, tone, and texture after several weeks of regular use
In confirmation of this finding, Gross et al
For a more in-depth anti-ageing approach, studies recommend taking at least 2.5 g to 10 g of collagen peptides daily